Shire files Gaucher's therapy in EU
This article was originally published in Scrip
Executive Summary
Shire has filed its velaglucerase alfa for type 1 Gaucher's disease in the EU. The drug was filed earlier this year in both the US and Canada, and a US launch could occur as soon as the first quarter of 2010.